Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kevin T Crofton Insider Profile
4 Followers
Kevin T Crofton, Director at Creo Medical, holds 4.75M shares in Creo Medical (Ticker: GB:CREO). Most recently, Kevin T Crofton Bought 1,179,000p shares of Creo Medical on Dec 16, 2024 for an estimated value of 200.67K.
Profitable Transactions
1 out of 2 Profitable Transactions
Average Return
-6.20%
Average return per transaction
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Kevin T Crofton's holdings
Insider Roles
Director
Roles that Kevin T Crofton holds in companies
Most Profitable Insider Trade
The most profitable trade made by Kevin T Crofton
Kevin T Crofton's Trading History
List of latest transactions for each holding click on a transaction to see Kevin T Crofton's performance on stock
You May Also Like
Kevin T Crofton insider profile FAQ
What is the percentage of profitable transactions made by Kevin T Crofton?
The percentage of profitable transactions made by Kevin T Crofton is 50%.
What is the average return per transaction made by Kevin T Crofton?
The average return per transaction made by Kevin T Crofton is -6.20%.
What stocks does Kevin T Crofton hold?
Kevin T Crofton holds: GB:CREO stocks.
What was Kevin T Crofton’s latest transaction?
Kevin T Crofton latest transaction was an Informative Buy of 200.67K.
What was Kevin T Crofton's most profitable transaction?
Kevin T Crofton’s most profitable transaction was an Informative Buy of GB:CREO stock on December 16, 2024. The return on the trade was 4.00%.
What is Kevin T Crofton's role in Creo Medical?
Kevin T Crofton's role in Creo Medical is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.